FDA Approves Foundation Medicine’s Liquid Biopsy Test as Companion Diagnostic for Novartis’ Tabrecta
Cambridge, MA-based Foundation Medicine (FMI) announced that the FDA greenlit its liquid biopsy assay as a companion diagnostic to Novartis’ kinase inhibitor, Tabrecta. Lung cancer is the second most common …
Read More